Trump nets nine more pharmas

Posted 23 December 2025 AM

Nine more Big Pharmas have signed Most Favoured Nation (MFN) agreements with the US in exchange for a three-year reprieve from tariffs.

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GSK, Gilead, MSD, Novartis and Sanofi have all reached agreements with the Trump administration to provide certain prescription medicines at reduced prices.

To see the whole article, please login

Popular

Who made PBAC's Christmas List?

Best pharma one-liners of 2025

First PBS listings of 2026 go to...

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (10)

Devices (1)

Devices Territory Manager - Brisbane

Other (11)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now